[go: up one dir, main page]

MX2021003156A - Treatment for non-alcoholic fatty liver disease. - Google Patents

Treatment for non-alcoholic fatty liver disease.

Info

Publication number
MX2021003156A
MX2021003156A MX2021003156A MX2021003156A MX2021003156A MX 2021003156 A MX2021003156 A MX 2021003156A MX 2021003156 A MX2021003156 A MX 2021003156A MX 2021003156 A MX2021003156 A MX 2021003156A MX 2021003156 A MX2021003156 A MX 2021003156A
Authority
MX
Mexico
Prior art keywords
liver disease
fatty liver
treatment
alcoholic fatty
nafld
Prior art date
Application number
MX2021003156A
Other languages
Spanish (es)
Inventor
LI Chiang J
Zoltan Derdak
Jifeng Liu
Original Assignee
1 Globe Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1 Globe Biomedical Co Ltd filed Critical 1 Globe Biomedical Co Ltd
Publication of MX2021003156A publication Critical patent/MX2021003156A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides novel methods of treating or preventing nonalcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH) in a mammal including a human.
MX2021003156A 2018-09-18 2019-09-18 Treatment for non-alcoholic fatty liver disease. MX2021003156A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862732644P 2018-09-18 2018-09-18
PCT/US2019/051790 WO2020061232A1 (en) 2018-09-18 2019-09-18 Treatment for non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
MX2021003156A true MX2021003156A (en) 2021-05-14

Family

ID=69888816

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003156A MX2021003156A (en) 2018-09-18 2019-09-18 Treatment for non-alcoholic fatty liver disease.

Country Status (13)

Country Link
US (1) US12318381B2 (en)
EP (1) EP3852753A4 (en)
JP (2) JP7557788B2 (en)
KR (1) KR20210079290A (en)
CN (1) CN112955143B (en)
AU (1) AU2019345297B2 (en)
BR (1) BR112021005086A2 (en)
CA (1) CA3113016A1 (en)
MX (1) MX2021003156A (en)
NZ (1) NZ774401A (en)
SG (1) SG11202102684VA (en)
TW (1) TWI825177B (en)
WO (1) WO2020061232A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7235312B2 (en) 2016-09-07 2023-03-08 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション Compositions and methods for treating insulin resistance
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
JP2022523333A (en) 2019-01-30 2022-04-22 トゥルーバインディング，インコーポレイテッド Anti-GAL3 antibody and its use
TW202206062A (en) * 2020-04-24 2022-02-16 美國坦普大學 高等教育聯邦系統 Methods for treatment of non-alcoholic steatohepatitis
US20230339871A1 (en) * 2020-08-18 2023-10-26 Metrea Biosciences, Inc. Compounds and methods of modulating 17b-hydroxysteroid dehydrogenase type 13

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100977A2 (en) 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
WO2009033033A2 (en) * 2007-09-06 2009-03-12 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
KR20150127249A (en) 2013-03-13 2015-11-16 보스톤 바이오메디칼, 인크. 3-(aryl or heteroaryl)methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
US20160368870A1 (en) 2013-06-20 2016-12-22 Boehringer Ingelheim International Gmbh Olefin substituted oxindoles having ampk activity
EP2886541A1 (en) 2013-12-19 2015-06-24 Sanofi Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases
WO2015112941A1 (en) * 2014-01-27 2015-07-30 Boston Biomedical, Inc. Novel methods for treating cancer
JPWO2017026119A1 (en) 2015-08-10 2018-05-24 大日本住友製薬株式会社 Method for purifying 5- (thiazol-4-yl) indoline-2-one derivatives
US20170105996A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries, Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
MA43190A (en) 2015-11-06 2018-09-12 Gemphire Therapeutics Inc TREATMENT OF MIXED DYSLIPIDEMIA
WO2018005444A2 (en) * 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
US20210275523A1 (en) * 2018-09-18 2021-09-09 1Globe Biomedical Co., Ltd. Treatment for obesity

Also Published As

Publication number Publication date
US12318381B2 (en) 2025-06-03
JP2022501436A (en) 2022-01-06
US20220040172A1 (en) 2022-02-10
CA3113016A1 (en) 2020-03-26
BR112021005086A2 (en) 2021-06-08
AU2019345297B2 (en) 2024-12-05
EP3852753A4 (en) 2022-06-08
AU2019345297A1 (en) 2021-04-29
JP2024163257A (en) 2024-11-21
EP3852753A1 (en) 2021-07-28
JP7557788B2 (en) 2024-09-30
CN112955143A (en) 2021-06-11
TWI825177B (en) 2023-12-11
KR20210079290A (en) 2021-06-29
NZ774401A (en) 2025-02-28
SG11202102684VA (en) 2021-04-29
TW202034910A (en) 2020-10-01
WO2020061232A1 (en) 2020-03-26
CN112955143B (en) 2023-10-13

Similar Documents

Publication Publication Date Title
NZ774401A (en) Treatment for non-alcoholic fatty liver disease
PH12017502359B1 (en) Glucagon and glp-1 co-agonist compounds
IL281093B1 (en) Combinations for treatment of nash/nafld and related diseases
MX2020001774A (en) Compositions and methods for treating cholestatic disease.
EA201692050A1 (en) TREATMENT OF NON-ALCOHOLIC FATIAL DISEASE OF THE LIVER AND NON-ALCOHOL STEATOGEPATITIS
MX2019006864A (en) Treatment of a disease of the gastrointestinal tract with a tnf inhibitor.
MX2022008100A (en) Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions.
MX2021006784A (en) Rnai constructs for inhibiting pnpla3 expression and methods of use thereof.
IL285989B1 (en) Method for treating fatty liver disease and/or steatohepatitis
IL283200A (en) Combination treatment of nafld and nash
PH12020500164A1 (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
IL266519A (en) Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash
IL314181B1 (en) Semaglutide for the treatment of non-alcoholic steatohepatitis
MX392496B (en) GLUCAGON RECEPTOR ANTAGONIST ANTIBODIES FOR USE IN THE TREATMENT OF OBESITY AND NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS.
IL284345A (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
RS66854B1 (en) Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease
MX2019002579A (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver.
EP4234536A3 (en) Amino-aryl-benzamide compounds and methods of use thereof
WO2021041561A3 (en) Treating non-alcoholic fatty liver disease and inflammatory steatohepatitis with slc25a1 inhibitors
EP3863643A4 (en) AZD3355 (LESOGABERAN) FOR THE TREATMENT AND PREVENTION OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER FIBROSIS AND OTHER LIVER DISEASES
MX2021001393A (en) Compositions for the treatment of graft versus host disease.
PT3595660T (en) Compounds for use in the prevention and/or treatment of non-alcoholic fat liver disease and non-alcoholic steatohepatitis
MX2020005445A (en) ANTI-huTNFR1 THERAPY OF NONALCOHOLIC STEATOHEPATITIS.
IL278077A (en) Method of treatment of non-alcoholic steatohepatitis, nash
EP3921338A4 (en) Targeting cd24-siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis